北京大学学报(医学版) ›› 2019, Vol. 51 ›› Issue (1): 145-150. doi: 10.19723/j.issn.1671-167X.2019.01.025

• 论著 • 上一篇    下一篇

hUTP14a在非小细胞肺癌组织中的表达

张春凤1,刘云2,陆敏3,杜晓娟4,()   

  1. 1. 北京大学基础医学院医学遗传学系,北京 100191
    2. 北京大学医药卫生分析中心,北京 100191
    3. 北京大学基础医学院病理学系,北京 100191
    4. 北京大学基础医学院细胞生物学系,北京 100191
  • 收稿日期:2018-09-27 出版日期:2019-02-18 发布日期:2019-02-26
  • 通讯作者: 杜晓娟 E-mail:duxiaojuan100@bjmu.edu.cn
  • 基金资助:
    国家自然科学基金(81874143)

Expression of hUTP14a in non-small cell lung cancer

Chun-feng ZHANG1,Yun LIU2,Min LU3,Xiao-juan DU4,()   

  1. 1. Department of Medical Genetics, Peking University School of Basic Medical Sciences, Beijing 100191, China
    2. Peking University Centre of Medical and Health Analysis, Beijing 100191, China
    3. Department of Pathology, Peking University School of Basic Medical Sciences, Beijing 100191, China
    4. Department of Cell Biology, Peking University School of Basic Medical Sciences, Beijing 100191, China
  • Received:2018-09-27 Online:2019-02-18 Published:2019-02-26
  • Contact: Xiao-juan DU E-mail:duxiaojuan100@bjmu.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China(81874143)

摘要:

目的:hUTP14a通过促进p53和Rb降解以及增强c-Myc致癌活性促进肿瘤的发生,且在人肝癌和结直肠癌组织中表达升高。本研究检测hUTP14a在非小细胞肺癌(non-small cell lung cancer, NSCLC)组织中的表达,并分析hUTP14a的表达水平与NSCLC患者临床特征的关系。方法:收集2003年5月至2006年4月在北京大学第三医院接受手术治疗并经过组织病理学确诊的123例NSCLC患者的组织蜡块标本(鳞状细胞癌53例,腺癌70例),采用免疫组织化学染色方法分析癌组织及其邻近癌旁非肿瘤组织中hUTP14a的表达水平,应用SPSS 17.0软件的χ 2检验,以患者的性别、年龄、组织类型、肿瘤大小、分化程度以及临床分期等临床病理特征进行分组,对组间肺癌组织中hUTP14a的表达率进行比较。结果:hUTP14a在肺癌组织中的阳性表达率为37.4%(46/123),在癌旁组织中的阳性表达率为0(0/123),在肺癌组织中的表达率显著高于癌旁非肿瘤组织(P<0.001);hUTP14a在肺腺癌中的表达率为48.6%(34/70),在鳞状细胞癌中的表达率为22.6%(12/53),均显著高于相应的癌旁组织[0 (0/70),0 (0/53)]; hUTP14a在肺腺癌中的表达率显著高于在鳞状细胞癌中的表达率(48.6% vs. 22.6%,χ 2=8.66,P=0.03)。进一步分析肺鳞状细胞癌、腺癌与各临床病理特征之间的关系发现,hUTP14a在病理分期(pTNM)晚期的肺鳞状细胞癌患者肿瘤组织中的表达率显著高于pTNM早期的鳞状细胞癌患者,而与肺腺癌的pTNM分期没有显著关联性,未见hUTP14a表达与肺癌的其他临床病理特征存在关联。结论:hUTP14a在肺癌组织中特异性表达升高,而且与肺鳞状细胞癌的pTNM分期具有关联性,提示hUTP14a有可能成为早期筛查诊断NSCLC的候选标志物。

关键词: hUTP14a, 非小细胞肺癌, 免疫组织化学, 鳞状细胞癌, 腺癌

Abstract:

Objective: Human U three protein 14a (hUTP14a) facilitates tumorigenesis through promoting p53 and Rb degradation as well as enhancing c-Myc oncogenic activity. Moreover, hUTP14a expression is up-regulated in human hepatocellular cancer and colorectal cancer tissues. In this study, the expression of hUTP14a in non-small cell lung cancer (NSCLC) tissues was evaluated by immunohistochemistry staining (IHC). The relationship between hUTP14a expression levels and the clinical characteristics of the NSCLC patients were analyzed. Methods: Lung cancer tissues and the adjacent non-cancerous tissues were collected from 123 cases of NSCLC patients including 53 cases of squamous cell carcinoma (SCC) and 70 cases of adenocarcinoma (ADC), who had accepted surgical resection at Peking University Third Hospital from May 2003 to April 2006. The expression level of hUTP14a was determined by IHC in human NSCLC tissues and the adjacent non-cancerous tissues. The associations between hUTP14a expression and the clinical pathological variables including gender, age, tumor size, histological type, differentiation degree and clinical pathological stage were analyzed using the Pearson’s χ 2 test. Results: The expression rate of hUTP14a in NSCLC tissues was significantly higher than that in the non-cancerous tissues (37.4% vs. 0, P<0.001). The expressions of hUTP14a in lung ADC and SCC were 48.6% and 20.6%, respectively. The expression rate of hUTP14a in both lung ADC and SCC was significantly higher than that in the adjacent non-cancerous tissues (P<0.001). In addition, the expression rate of hUTP14a in lung ADC was significantly higher than that in SCC (χ 2=8.66, P=0.003). Furthermore, the expression rate of hUTP14a in the late pTNM stage of SCC was significantly higher than that in the early pTNM stage of SCC while hUTP14a expression level was not associated with pTNM stage of ADC. No correlation was found between hUTP14a expression and the other clinical pathologic features of the patients. Conclusion: Expression of hUTP14a was up-regulated in NSCLC tissues and was correlated with pTNM stage of SCC, suggesting that hUTP14a might possess a potential as a candidate marker for the early diagnosis screening of NSCLC.

Key words: hUTP14a, non-small-cell lung carcinoma, Immunohistochemistry, Squamous cell carcinoma, Adenocarcinoma

中图分类号: 

  • R734.2

图1

免疫组织化学染色显示hUTP14a在肺癌组织中的表达(×400)"

表1

123例肺癌患者临床特征及hUTP14a表达阳性率*"

Clinicopathologic variables hUTP14a positive rate, n (%)
Total (n=123) SCC (n=53) Adenocarcinoma (n=70)
Gender (n=123)
Male (n=74) 25 (33.8) 10 (18.9) 15 (21.4)
Female (n=49) 21 (42.9) 2 (3.8) 19 (27.1)
Age/years (n=123)
≤60 (n=55) 20 (36.4) 8 (15.1) 12 (17.1)
>60 (n=68) 26 (38.2) 4 (7.5) 22 (31.4)
Tumor size/cm (n=123)
≤3 (n=81) 32 (39.5) 7 (13.2) 25 (35.7)
>3 (n=42) 14 (33.3) 5 (9.4) 9 (12.9)
Differentiationgrade (n=112)
Poorly differentiated (n=22) 8 (36.3) 2 (3.8) 6 (8.6)
Moderately differentiated (n=78) 30 (38.5) 6 (11.3) 24 (34.3)
Highly differentiated (n=12) 4 (33.3) 2 (3.8) 2 (2.9)
pTNM stage (n=101)
Ⅰ+Ⅱ (n=64) 16 (25.0) 3 (5.7) 13 (18.6)
Ⅲ+Ⅳ (n=37) 13 (35.1) 9 (16.9) 4 (5.7)

表2

123例肺癌患者hUTP14a表达与临床病理特征之间的关系*"

Clinicopathologic variables Total (n=123), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=123)
Male (n=74) 49 (66.2) 25 (33.8)
Female (n=49) 28 (57.1) 21 (42.9) 1.037 0.309
Age/years (n=123)
≤60 (n=55) 35 (63.6) 20 (36.4)
>60 (n=68) 42(61.8) 26 (38.2) 0.045 0.831
Histopathology (n=123)
SCC (n=53) 41 (77.4) 12 (22.6)
Adenocarcinoma (n=70) 36 (51.4) 34 (48.6) 8.662 0.003
Tumor size/cm (n=123)
≤3 (n=81) 49 (60.5) 32 (39.5)
>3 (n=42) 28 (66.7) 14 (33.3) 0.450 0.502
Differentiation grade (n=112)
Poorly differentiated (n=22) 14 (63.6) 8 (36.4)
Moderately differentiated (n=78) 48 (61.5) 30 (38.5)
Highly differentiated (n=12) 8 (66.7) 4 (33.3) 0.132 0.936
pTNM stage (n=101)
Ⅰ+Ⅱ (n=64) 48 (75.0) 16 (25.0)
Ⅲ+Ⅳ(n=37) 24 (64.9) 13 (35.1) 1.177 0.278

表3

53例肺鳞状细胞癌患者hUTP14a表达与临床病理特征之间的关系*"

Clinicopathologic variables SCC (n=53), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=53)
Male (n=44) 34 (77.3) 10 (22.7)
Female (n=9) 7 (77.8) 2 (22.2) 0.001 0.974
Age/years (n=53)
≤60 (n=24) 16 (66.7) 8 (33.3)
>60 (n=29) 25 (86.2) 4 (13.8) 2.863 0.091
Tumor size/cm (n=53)
≤3 (n=27) 20 (74.1) 7 (25.9)
>3 (n=26) 21 (80.8) 5 (19.2) 0.339 0.560
Differentiation grade (n=42)
Poorly differentiated (n=10) 8 (80.0) 2 (20.0)
Moderately differentiated (n=26) 20 (76.9) 6 (23.1)
Highly differentiated (n=6) 4 (66.7) 2 (33.3) 0.388 0.824
pTNM stage (n=54)
Ⅰ+Ⅱ (n=29) 26 (89.6) 3 (10.3)
Ⅲ+Ⅳ(n=25) 17 (68.0) 8 (32.0) 3.959 0.047

表4

70例肺腺癌患者hUTP14a表达与临床病理特征之间的关系*"

Clinicopathologic variables Adenocarcinoma (n=70), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=70)
Male (n=30) 15 (50.0) 15 (50.0)
Female (n=40) 21 (52.5) 19 (47.5) 0.043 0.836
Age/years (n=70)
≤60 (n=31) 19 (61.3) 12 (38.7)
>60 (n=39) 17 (43.6) 22 (56.4) 2.166 0.141
Tumor size/cm (n=70)
≤3 (n=54) 29 (53.7) 25 (46.3)
>3 (n=16) 7 (43.7) 9 (56.3) 0.490 0.484
Differentiation grade (n=70)
Poorly differentiated (n=12) 6 (50.0) 6 (50.0)
Moderately differentiated (n=52) 28(53.8) 24 (46.2)
Highly differentiated (n=6) 4 (66.7) 2 (33.3) 0.463 0.793
pTNM stage (n=47)
Ⅰ+Ⅱ (n=35) 22 (62.9) 13 (37.1)
Ⅲ+Ⅳ(n=12) 7 (58.3) 5 (12.9) 0.077 0.781
[1] Zhang L, Li M, Wu N , et al. Time trends in epidemiologic cha-racteristics and imaging features of lung adenocarcinoma: a population study of 21,113 cases in China[J]. PLoS One, 2015,10(8):e0136727.
doi: 10.1371/journal.pone.0136727 pmid: 4552856
[2] 王媛媛, 毕玉, 王在翔 , 等. 山东省肺癌患者生存分析[J]. 中国卫生统计, 2018,35(1):111-116.
[3] 黄文彦, 刘凯珊 . 以新视角观察p53家族在肺癌发生及治疗中的独特作用[J]. 中国肺癌杂志, 2013,16(8):422-425.
doi: 10.3779/j.issn.1009-3419.2013.08.06
[4] 李相国, 齐景宪, 易明福 . P16、Rb和PCNA在非小细胞肺癌的表达及临床意义[J]. 临床肺科杂志, 2008,13(8):1002-1004.
doi: 10.3969/j.issn.1009-6663.2008.08.023
[5] Scheffner M, Huibregtse JM, Vierstra RD , et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53[J]. Cell, 1993,75(3):495-505.
doi: 10.1016/0092-8674(93)90384-3 pmid: 8221889
[6] Uchida C, Miwa S, Kitagawa K , et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation[J]. EMBO J, 2005,24(1):160-169.
doi: 10.1038/sj.emboj.7600486 pmid: 15577944
[7] Sdek P, Ying H, Chang DL , et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein[J]. Mol Cell, 2005,20(5):699-708.
doi: 10.1016/j.molcel.2005.10.017 pmid: 16337594
[8] Hu LL, Wang JN, Liu Y , et al. A small ribosomal subunit (SSU) processome component, the human U3 protein 14A (hUTP14A) binds p53 and promotes p53 degradation[J]. J Biol Chem, 2011,286(4):3119-3128.
doi: 10.1074/jbc.M110.157842 pmid: 21078665
[9] Liu HJ, Wang JN, Liu Y , et al. Human U3 protein14a is a novel type ubiquitin ligase that binds RB and promotes RB degradation depending on a leucine-rich region[J]. Biochim Biophys Acta Mol Cell Res, 2018,1865(11 Pt A):1611-1620.
doi: 10.1016/j.bbamcr.2018.08.016
[10] Zhang JY, Ren PW, Xu D , et al. Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc [J]. Cancer Letters, 2018, 440- 441:106-115.
doi: 10.1016/j.canlet.2018.10.010
[11] Zhang JY, Xu D, Liu ZZ , et al. Human U three protein 14a expression is increased in hepatocellular carcinoma and associated with poor prognosis[J]. Chin Med J (Engl), 2017,130(4):470-476.
doi: 10.4103/0366-6999.199839 pmid: 5324385
[12] Ma T, Lu CX, Guo YF , et al. Human U3 protein 14a plays an anti-apoptotic role in cancer cells[J]. Bio Chem, 2017,398(11):1247-1257.
[13] Groome PA, Bolejack V, Crowley JJ , et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J]. J Thorac Oncol, 2007,2(8):694-705.
doi: 10.1097/JTO.0b013e31812d05d5 pmid: 17762335
[14] Zhang Y, Xiong Y, Yarbrough WG . ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways[J]. Cell, 1998,92(6):725-734.
doi: 10.1016/S0092-8674(00)81401-4
[15] Leduc C, Claverie P, Eymin B , et al. p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation[J]. Oncogene, 2006,25(30):4147-4154.
doi: 10.1038/sj.onc.1209446 pmid: 16501607
[16] Bozcuk H, Gumus A, Ozbilim G , et al. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer[J]. Med Sci Monit, 2005,11(6):11-20.
doi: 10.1051/medsci/2005216-7669 pmid: 15917726
[17] 张丽华, 侯振江 . p53在肺癌研究中的进展[J]. 临床肺科杂志, 2006,11(1):59-60.
doi: 10.3969/j.issn.1009-6663.2006.01.030
[1] 周传香,周正,张晔,刘晓筱,高岩. 28例口腔基底样鳞状细胞癌的临床病理分析[J]. 北京大学学报(医学版), 2022, 54(1): 62-67.
[2] 苏俊琪,宋扬,谢尚. 口腔鳞状细胞癌患者修复重建术后感染的病原学特征及感染风险预测模型的构建[J]. 北京大学学报(医学版), 2022, 54(1): 68-76.
[3] 白杲琛,宋毅,金杰,虞巍,何志嵩. 多西他赛联合卡铂治疗转移性去势抵抗性前列腺癌的临床疗效[J]. 北京大学学报(医学版), 2021, 53(4): 686-691.
[4] 于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报(医学版), 2021, 53(4): 640-646.
[5] 邱敏,费月阳,邓绍晖,刘承,卢剑,何为,陆敏,田晓军,张树栋,马潞林. 后肾腺瘤的诊治经验及文献回顾[J]. 北京大学学报(医学版), 2021, 53(2): 417-419.
[6] 廖栩鹤,王荣福,刘萌,陈雪祺,熊焰,农琳,殷雷,张炳晔,杜毓菁. 18F-FDG PET/CT半定量参数、表皮生长因子受体和间变淋巴瘤激酶基因突变对肺腺癌患者预后评估的价值[J]. 北京大学学报(医学版), 2021, 53(2): 246-254.
[7] 王迎春,黄永辉,常虹,姚炜,闫秀娥,李柯,张耀鹏,郑炜. 十二指肠乳头息肉良、恶性病变比较及活检准确性[J]. 北京大学学报(医学版), 2021, 53(1): 204-209.
[8] 池彦廷,张延平,张秋露,刘翠苓,李斌斌. 唾液腺干燥综合征继发黏膜相关淋巴组织淋巴瘤的临床病理分析[J]. 北京大学学报(医学版), 2021, 53(1): 40-45.
[9] 苏雷震,陈洁,李显,季平. 沙利霉素对口腔鳞癌细胞增殖和凋亡的影响[J]. 北京大学学报(医学版), 2020, 52(5): 902-906.
[10] 徐涛,韩敬丽,姚伟娟. 雄激素剥夺治疗相关心血管疾病的机制与临床对策[J]. 北京大学学报(医学版), 2020, 52(4): 607-609.
[11] 朱巧,任翠,张艳,李美娇,王晓华. 能谱CT诊断非小细胞肺癌纵隔淋巴结转移的应用价值[J]. 北京大学学报(医学版), 2020, 52(4): 730-737.
[12] 李文卿,任思楣,龙星博,田雨青. 棕榈酰化蛋白质组学分析揭示前列腺癌细胞中雄激素促进代谢相关蛋白棕榈酰化修饰[J]. 北京大学学报(医学版), 2020, 52(2): 227-233.
[13] 孙奎霞,闫存玲,李志艳,刘平,张伟,何群. 前列腺特异性抗原同源异构体2及其衍生指标在预测前列腺癌病理分级中的价值[J]. 北京大学学报(医学版), 2020, 52(2): 234-239.
[14] 马茹,李鑫宝,闫风彩,林育林,李雁. 肿瘤间质比评估阑尾来源腹膜假黏液瘤的临床价值[J]. 北京大学学报(医学版), 2020, 52(2): 240-246.
[15] 欧阳雨晴,倪莲芳,刘新民. 恶性孤立性肺结节患者预后因素分析[J]. 北京大学学报(医学版), 2020, 52(1): 158-162.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究(英文稿)[J]. 北京大学学报(医学版), 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报(医学版), 2009, 41(2): 125 -128 .
[3] 成刚, 钱振华, 胡军. 艾滋病项目自愿咨询检测的技术效率分析[J]. 北京大学学报(医学版), 2009, 41(2): 135 -140 .
[4] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报(医学版), 2009, 41(2): 158 -161 .
[5] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报(医学版), 2009, 41(2): 217 -220 .
[6] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报(医学版), 2009, 41(1): 52 -55 .
[7] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报(医学版), 2009, 41(3): 297 -301 .
[8] Jian-wei GU, Emily YOUNG, Zhi-jun PAN, Kevan B. TUCKER, Megan SHPARAGO, Min HUANG, Amelia Purser BAILEY. SD大鼠长期高盐饮食可导致其高血压并改变肾细胞因子基因表达谱[J]. 北京大学学报(医学版), 2009, 41(5): 505 -515 .
[9] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报(医学版), 2009, 41(5): 599 -601 .
[10] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报(医学版), 2009, 41(5): 516 -520 .